Flag of the European Union EU Clinical Trials Register Help

Clinical trials

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

  • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).


    The EU Clinical Trials Register currently displays   44334   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     

    < Back to search results

    Download PDF

    Clinical Trial Results:
    A RANDOMIZED, DOUBLE BLIND, PLACEBO–CONTROLLED, PHASE 3 STUDY TO ASSESS THE SAFETY AND EFFICACY OF ART-123 IN SUBJECTS WITH SEVERE SEPSIS AND COAGULOPATHY

    Summary
    EudraCT number
    2012-002251-42
    Trial protocol
    BE   NL   HU   FI   CZ   ES   BG   GB   DE   GR  
    Global end of trial date
    28 Feb 2019

    Results information
    Results version number
    v1(current)
    This version publication date
    12 Apr 2020
    First version publication date
    12 Apr 2020
    Other versions

    Trial information

    Close Top of page
    Trial identification
    Sponsor protocol code
    3-001
    Additional study identifiers
    ISRCTN number
    -
    US NCT number
    NCT01598831
    WHO universal trial number (UTN)
    -
    Sponsors
    Sponsor organisation name
    Asahi Kasei Pharma America Corporation
    Sponsor organisation address
    200 5th Avenue, Waltham, United States,
    Public contact
    David Fineberg, MD Medical Monitor, Asahi Kasei Pharma America Corporation, 1 7815307191, dfineberg@akpamerica.com
    Scientific contact
    David Fineberg, MD Medical Monitor, Asahi Kasei Pharma America Corporation, 1 7815307191, dfineberg@akpamerica.com
    Paediatric regulatory details
    Is trial part of an agreed paediatric investigation plan (PIP)
    No
    Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?
    No
    Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?
    No
    Results analysis stage
    Analysis stage
    Final
    Date of interim/final analysis
    13 May 2019
    Is this the analysis of the primary completion data?
    Yes
    Primary completion date
    28 Feb 2019
    Global end of trial reached?
    Yes
    Global end of trial date
    28 Feb 2019
    Was the trial ended prematurely?
    No
    General information about the trial
    Main objective of the trial
    1. To evaluate whether ART-123, when administered to subjects with bacterial infection complicated by at least one organ dysfunction (septic shock and/or respiratory failure) and coagulopathy, can reduce mortality. 2. To evaluate the safety of ART-123 in this patient population.
    Protection of trial subjects
    Critically ill subjects treated and monitored in an ICU or acute care setting. Safety assessments for adverse events, ECGs and laboratory tests were conducted to ensure subject safety.
    Background therapy
    In addition to the IMP treatment per study protocol, subjects were treated for sepsis according to the standard of care of the institution.
    Evidence for comparator
    No comparators used.
    Actual start date of recruitment
    29 Aug 2012
    Long term follow-up planned
    Yes
    Long term follow-up rationale
    Efficacy
    Long term follow-up duration
    12 Months
    Independent data monitoring committee (IDMC) involvement?
    Yes
    Population of trial subjects
    Number of subjects enrolled per country
    Country: Number of subjects enrolled
    Netherlands: 49
    Country: Number of subjects enrolled
    Spain: 20
    Country: Number of subjects enrolled
    United Kingdom: 10
    Country: Number of subjects enrolled
    Belgium: 68
    Country: Number of subjects enrolled
    Bulgaria: 2
    Country: Number of subjects enrolled
    Czech Republic: 21
    Country: Number of subjects enrolled
    Finland: 37
    Country: Number of subjects enrolled
    France: 149
    Country: Number of subjects enrolled
    Germany: 7
    Country: Number of subjects enrolled
    Greece: 1
    Country: Number of subjects enrolled
    Hungary: 1
    Country: Number of subjects enrolled
    Argentina: 1
    Country: Number of subjects enrolled
    Australia: 38
    Country: Number of subjects enrolled
    Brazil: 19
    Country: Number of subjects enrolled
    Canada: 46
    Country: Number of subjects enrolled
    Colombia: 2
    Country: Number of subjects enrolled
    Croatia: 11
    Country: Number of subjects enrolled
    India: 85
    Country: Number of subjects enrolled
    Israel: 19
    Country: Number of subjects enrolled
    Korea, Republic of: 6
    Country: Number of subjects enrolled
    New Zealand: 11
    Country: Number of subjects enrolled
    Peru: 5
    Country: Number of subjects enrolled
    Russian Federation: 111
    Country: Number of subjects enrolled
    Serbia: 2
    Country: Number of subjects enrolled
    Taiwan: 8
    Country: Number of subjects enrolled
    United States: 71
    Worldwide total number of subjects
    800
    EEA total number of subjects
    376
    Number of subjects enrolled per age group
    In utero
    0
    Preterm newborn - gestational age < 37 wk
    0
    Newborns (0-27 days)
    0
    Infants and toddlers (28 days-23 months)
    0
    Children (2-11 years)
    0
    Adolescents (12-17 years)
    0
    Adults (18-64 years)
    462
    From 65 to 84 years
    305
    85 years and over
    33

    Subject disposition

    Close Top of page
    Recruitment
    Recruitment details
    This study was conducted at 319 sites in 27 countries; of these, 159 study sites (in 26 countries) assigned participants to study drug treatment. First participant was randomized on Oct 29, 2012 and the last participant was randomized on Mar 8, 2018. Last participant completed long term follow-up (survival only) on Feb 28, 2019.

    Pre-assignment
    Screening details
    Of 946 consented participants, 816 were randomized to study treatment and 800 received at least one dose of study treatment, 571 completed of 6 consecutive dose. Primary endpoint was assessed at Day 28.

    Pre-assignment period milestones
    Number of subjects started
    816 [1]
    Number of subjects completed
    800

    Pre-assignment subject non-completion reasons
    Reason: Number of subjects
    did not receive a dose of drug: 16
    Notes
    [1] - The number of subjects reported to have started the pre-assignment period are not the same as the worldwide number enrolled in the trial. It is expected that these numbers will be the same.
    Justification: 816 subjects were enrolled (i.e. randomized) into the 3-001 study but 16 of these subjects did not receive a dose of IMP.
    Period 1
    Period 1 title
    Overall trial (overall period)
    Is this the baseline period?
    Yes
    Allocation method
    Randomised - controlled
    Blinding used
    Double blind
    Roles blinded
    Subject, Investigator, Monitor
    Blinding implementation details
    Subjects were randomly assigned in a 1:1 ratio to receive either ART-123 or placebo. A vendor, Almac Clinical Services provided an automatic system that generated a unique randomization number to the site at the baseline visit and for an assigned IMP kit number. The study site and Sponsor were blinded. Lab samples were coded and kept blinded. A DMC was unblinded for monitoring safety and only CRO personnel for unblinding safety reports or for follow-up of antibody positive tests were unblinded.

    Arms
    Are arms mutually exclusive
    Yes

    Arm title
    ART-123
    Arm description
    Received at least one dose of study drug: ART-123 (thrombomodulin alfa) dosage administered intravenously 0.06 mg/kg/day (up to a maximum dose of 6 mg/day) for 6 consecutive days.
    Arm type
    Experimental

    Investigational medicinal product name
    ART-123
    Investigational medicinal product code
    ART-123
    Other name
    thrombomodulin alfa
    Pharmaceutical forms
    Solution for infusion
    Routes of administration
    Intravenous bolus use
    Dosage and administration details
    ART-123 was are administered at the equivalent dose of 0.06 mg/kg/day up to a maximum dose of 6.0 mg/day for six consecutive days. ART-123 is given by intravenous bolus or rapid IV infusion, in which case 0.06 mg/kg/day up to a maximum dose of 6.0 mg/day is diluted in 50 mL of NS and given over a period of 15 minutes. ART-123 is supplied as individual glass ampules containing 6.0 mg of formulated drug in 1 mL of total volume; with an overfill of 0.1mL. The total volume of each ampule equals 1.1 mL. Stable for up to 18 months when stored at 2°C–8°C. Photostability studies indicate that ART-123 is sensitive to light. The investigational drug product is kept in closed cartons and should be protected from sunlight at all times.

    Arm title
    Placebo
    Arm description
    Subject received at least one dose of study treatment : Placebo was administered intravenously at the equivalent dose of 0.06 mg/kg/day up to a maximum dose of 6.0 mg/day for six consecutive days.
    Arm type
    Placebo

    Investigational medicinal product name
    Placebo
    Investigational medicinal product code
    Placebo
    Other name
    Placebo
    Pharmaceutical forms
    Solution for infusion
    Routes of administration
    Intravenous bolus use
    Dosage and administration details
    Placebo was administered at the equivalent dose of 0.06 mg/kg/day up to a maximum dose of 6.0 mg/day for six days. Placebo was given by intravenous bolus or rapid IV infusion, in which case 0.06 mg/kg/day up to a maximum dose of 6.0 mg/day is diluted in 50mL of NS and given over a period of 15 minutes. Placebo for this study was supplied as identically labeled, individual glass ampules in 1 mL of total volume; with an overfill of 0.1mL. The total volume of each ampule equals 1.1 mL. Placebo was maintained refrigerated at 2°C–8°C and protected from light during storage.

    Number of subjects in period 1
    ART-123 Placebo
    Started
    395
    405
    Completed
    283
    278
    Not completed
    112
    127
         Adverse event, serious fatal
    104
    117
         Consent withdrawn by subject
    1
    1
         PI decision
    1
    -
         Various reasons
    6
    -
         varying reasons
    -
    9

    Baseline characteristics

    Close Top of page
    Baseline characteristics reporting groups
    Reporting group title
    ART-123
    Reporting group description
    Received at least one dose of study drug: ART-123 (thrombomodulin alfa) dosage administered intravenously 0.06 mg/kg/day (up to a maximum dose of 6 mg/day) for 6 consecutive days.

    Reporting group title
    Placebo
    Reporting group description
    Subject received at least one dose of study treatment : Placebo was administered intravenously at the equivalent dose of 0.06 mg/kg/day up to a maximum dose of 6.0 mg/day for six consecutive days.

    Reporting group values
    ART-123 Placebo Total
    Number of subjects
    395 405 800
    Age categorical
    Baseline Analysis Population, Full Analysis Set - all randomized and dosed subjects.
    Units: Subjects
        Adults (18-64 years)
    231 231 462
        From 65-84 years
    146 159 305
        85 years and over
    18 15 33
    Gender categorical
    Baseline Analysis Population, Full Analysis Set - All randomized and dosed subjects.
    Units: Subjects
        Female
    179 184 363
        Male
    216 221 437

    End points

    Close Top of page
    End points reporting groups
    Reporting group title
    ART-123
    Reporting group description
    Received at least one dose of study drug: ART-123 (thrombomodulin alfa) dosage administered intravenously 0.06 mg/kg/day (up to a maximum dose of 6 mg/day) for 6 consecutive days.

    Reporting group title
    Placebo
    Reporting group description
    Subject received at least one dose of study treatment : Placebo was administered intravenously at the equivalent dose of 0.06 mg/kg/day up to a maximum dose of 6.0 mg/day for six consecutive days.

    Primary: 28-Day All-cause Mortality

    Close Top of page
    End point title
    28-Day All-cause Mortality
    End point description
    Mortality status 28 days was determined by evaluating the date of death if a subject died, or the last known contact date if the subject was not known to have died. If the date of death was 28 days or less from the start of treatment the subject was classified as dead at 28 days after the start of treatment (Mortality Day 28).
    End point type
    Primary
    End point timeframe
    Through Day 28
    End point values
    ART-123 Placebo
    Number of subjects analysed
    395
    405
    Units: Participants
    106
    119
    Statistical analysis title
    28-Day All-cause Mortality Analysis
    Comparison groups
    ART-123 v Placebo
    Number of subjects included in analysis
    800
    Analysis specification
    Pre-specified
    Analysis type
    superiority
    P-value
    = 0.318 [1]
    Method
    Cochran-Mantel-Haenszel
    Parameter type
    Risk difference (RD)
    Point estimate
    -2.55
    Confidence interval
         level
    95%
         sides
    2-sided
         lower limit
    -3.68
         upper limit
    8.77
    Notes
    [1] - p-value is calculated value, not the a priori threshold for statistical significance. The threshold for statistical significance was a two sided 5%. Estimation Comment: Rates by Arm are 26.8% for ART-123 and 29.4% for Placebo

    Primary: On-Treatment Serious Major Bleeding Events – Primary Safety outcome measure

    Close Top of page
    End point title
    On-Treatment Serious Major Bleeding Events – Primary Safety outcome measure [2]
    End point description
    On-treatment Serious Major Bleeding Events collected as Serious Adverse Events and defined as: any intracranial hemorrhage, any life-threatening bleeding, any bleeding event classified as serious (e.g., resulting in permanent morbidity), or any bleeding that required the administration of 1440 ml (typically 6 units) of packed red cells over two consecutive days. (Investigator assessment for seriousness criteria.)
    End point type
    Primary
    End point timeframe
    Through Day 28
    Notes
    [2] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
    Justification: Statistical analysis was only performed on 28-day mortality. All other endpoints only recorded participant counts per arm.
    End point values
    ART-123 Placebo
    Number of subjects analysed
    395 [3]
    404 [4]
    Units: Participants
    23
    16
    Notes
    [3] - Safety population: all subjects who received at least 1 dose of study drug
    [4] - Safety population: all subjects who received at least 1 dose of study drug
    No statistical analyses for this end point

    Secondary: Follow up all-cause mortality at 3 months

    Close Top of page
    End point title
    Follow up all-cause mortality at 3 months
    End point description
    Subject whose status was alive, or unknown was censored at the last available date that subject was known to be alive.
    End point type
    Secondary
    End point timeframe
    3 months
    End point values
    ART-123 Placebo
    Number of subjects analysed
    395
    405
    Units: Participants
    126
    136
    No statistical analyses for this end point

    Secondary: Resolution of organ dysfunction as measured through day 28 by shock free and alive days

    Close Top of page
    End point title
    Resolution of organ dysfunction as measured through day 28 by shock free and alive days
    End point description
    The number of event free and alive days was calculated as Alive Days - Event Days. Shock days was defined as the number of days on concomitant vasopressor medication as collected in the eCRF.
    End point type
    Secondary
    End point timeframe
    Through Day 28
    End point values
    ART-123 Placebo
    Number of subjects analysed
    395
    405
    Units: Days
        arithmetic mean (standard deviation)
    17.6 ( 10.5 )
    17.6 ( 10.56 )
    No statistical analyses for this end point

    Secondary: Resolution of organ dysfunction as measured through day 28 by ventilator free and alive days

    Close Top of page
    End point title
    Resolution of organ dysfunction as measured through day 28 by ventilator free and alive days
    End point description
    The number of event free and alive days was calculated as Alive Days - Event Days. Ventilator days was defined as the number of days on assisted breathing as collected in the eCRF.
    End point type
    Secondary
    End point timeframe
    Through Day 28
    End point values
    ART-123 Placebo
    Number of subjects analysed
    395
    405
    Units: Days
        arithmetic mean (standard deviation)
    15.8 ( 11.75 )
    14.5 ( 11.90 )
    No statistical analyses for this end point

    Secondary: Resolution of organ dysfunction as measured through day 28 by dialysis free and alive days

    Close Top of page
    End point title
    Resolution of organ dysfunction as measured through day 28 by dialysis free and alive days
    End point description
    The number of event free and alive days was calculated as Alive Days - Event Days. Dialysis days was defined as the number of days on dialysis as collected in the eCRF
    End point type
    Secondary
    End point timeframe
    Through Day 28
    End point values
    ART-123 Placebo
    Number of subjects analysed
    395
    405
    Units: Days
        arithmetic mean (standard deviation)
    20.2 ( 11.05 )
    19.6 ( 11.21 )
    No statistical analyses for this end point

    Secondary: Presence of Anti-drug antibodies up to 18 months

    Close Top of page
    End point title
    Presence of Anti-drug antibodies up to 18 months
    End point description
    Blood samples for analysis of anti-ART-123 antibody were obtained on Day 1 and Day 28 or at early termination. All subjects that developed anti-ART-123 antibodies were followed for blood draw and medical evaluation at 3 month intervals until their serum antibody titer results became negative for a maximum duration of 18 months (ADA Positive Subject Follow-Up).
    End point type
    Secondary
    End point timeframe
    18 Months
    End point values
    ART-123 Placebo
    Number of subjects analysed
    395 [5]
    404 [6]
    Units: Participants
    0
    0
    Notes
    [5] - Safety population: all subjects who received at least 1 dose of study drug
    [6] - Safety population: all subjects who received at least 1 dose of study drug
    No statistical analyses for this end point

    Post-hoc: Day 28 Mortality in Subjects with INR > 1.4 at Baseline and PLT > 30x10 9th/L at Baseline

    Close Top of page
    End point title
    Day 28 Mortality in Subjects with INR > 1.4 at Baseline and PLT > 30x10 9th/L at Baseline
    End point description
    Post-hoc analysis of Full Analysis Set. Target subjects: Approximately 80% of patients (634/800) maintained protocol-specified eligibility for coagulopathy (PT-INR >1.40 and PLT >30×109/L before initiating the first dose of study drug (baseline).
    End point type
    Post-hoc
    End point timeframe
    Through Day 28
    End point values
    ART-123 Placebo
    Number of subjects analysed
    307 [7]
    327 [8]
    Units: Participants
    82
    105
    Notes
    [7] - Subjects with INR > 1.4 at Baseline and PLT > 30K at Baseline
    [8] - Subjects with INR > 1.4 at Baseline and PLT > 30K at Baseline
    No statistical analyses for this end point

    Adverse events

    Close Top of page
    Adverse events information
    Timeframe for reporting adverse events
    Adverse events were collected between randomization and through Day 28. For SAE, collection started from the time of authorization to randomize the participants.
    Adverse event reporting additional description
    AEs were analyzed using a safety population that includes all subjects who received at least 1 dose of study drug. A treatment-emergent adverse event (TEAE) is defined as any AE following exposure to study treatment.
    Assessment type
    Systematic
    Dictionary used for adverse event reporting
    Dictionary name
    MedDRA
    Dictionary version
    20.0
    Reporting groups
    Reporting group title
    ART-123
    Reporting group description
    ART-123 (thrombomodulin alfa) dosage administered intravenously 0.06 mg/kg/day (up to a maximum dose of 6 mg/day) for 6 consecutive days. Safety population that includes all subjects who received at least 1 dose of study drug. Any subjects receiving both ART-123 and placebo were included in the ART-123 group.

    Reporting group title
    Placebo
    Reporting group description
    Placebo was administered intravenously at an equivalent dosage of 0.06 mg/kg/day (up to a maximum dose of 6 mg/day) for 6 consecutive days. Safety population that includes all subjects who received at least 1 dose of study drug. Any subjects receiving both ART-123 and placebo were included in the ART-123 group.

    Serious adverse events
    ART-123 Placebo
    Total subjects affected by serious adverse events
         subjects affected / exposed
    206 / 396 (52.02%)
    202 / 404 (50.00%)
         number of deaths (all causes)
    108
    119
         number of deaths resulting from adverse events
    7
    5
    Neoplasms benign, malignant and unspecified (incl cysts and polyps)
    Pancreatic carcinoma
         subjects affected / exposed
    0 / 396 (0.00%)
    1 / 404 (0.25%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 1
    Prostate cancer
         subjects affected / exposed
    1 / 396 (0.25%)
    0 / 404 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Tumour haemorrhage
         subjects affected / exposed
    0 / 396 (0.00%)
    1 / 404 (0.25%)
         occurrences causally related to treatment / all
    0 / 0
    1 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Vascular disorders
    Extremity necrosis
         subjects affected / exposed
    6 / 396 (1.52%)
    6 / 404 (1.49%)
         occurrences causally related to treatment / all
    1 / 6
    0 / 6
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Shock
         subjects affected / exposed
    4 / 396 (1.01%)
    7 / 404 (1.73%)
         occurrences causally related to treatment / all
    0 / 4
    2 / 7
         deaths causally related to treatment / all
    0 / 3
    2 / 6
    Deep vein thrombosis
         subjects affected / exposed
    2 / 396 (0.51%)
    4 / 404 (0.99%)
         occurrences causally related to treatment / all
    0 / 2
    0 / 4
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Shock haemorrhagic
         subjects affected / exposed
    6 / 396 (1.52%)
    0 / 404 (0.00%)
         occurrences causally related to treatment / all
    4 / 6
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Hypotension
         subjects affected / exposed
    1 / 396 (0.25%)
    2 / 404 (0.50%)
         occurrences causally related to treatment / all
    0 / 1
    1 / 2
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Arterial occlusive disease
         subjects affected / exposed
    2 / 396 (0.51%)
    0 / 404 (0.00%)
         occurrences causally related to treatment / all
    0 / 2
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Peripheral ischaemia
         subjects affected / exposed
    1 / 396 (0.25%)
    1 / 404 (0.25%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Aortic thrombosis
         subjects affected / exposed
    1 / 396 (0.25%)
    0 / 404 (0.00%)
         occurrences causally related to treatment / all
    1 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Arterial haemorrhage
         subjects affected / exposed
    0 / 396 (0.00%)
    1 / 404 (0.25%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Arterial thrombosis
         subjects affected / exposed
    1 / 396 (0.25%)
    0 / 404 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Circulatory collapse
         subjects affected / exposed
    0 / 396 (0.00%)
    1 / 404 (0.25%)
         occurrences causally related to treatment / all
    0 / 0
    1 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Haemorrhage
         subjects affected / exposed
    1 / 396 (0.25%)
    0 / 404 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Peripheral coldness
         subjects affected / exposed
    0 / 396 (0.00%)
    1 / 404 (0.25%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Venous thrombosis limb
         subjects affected / exposed
    0 / 396 (0.00%)
    1 / 404 (0.25%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    General disorders and administration site conditions
    Multiple organ dysfunction syndrome
         subjects affected / exposed
    24 / 396 (6.06%)
    28 / 404 (6.93%)
         occurrences causally related to treatment / all
    0 / 24
    2 / 28
         deaths causally related to treatment / all
    0 / 23
    1 / 27
    Death
         subjects affected / exposed
    0 / 396 (0.00%)
    2 / 404 (0.50%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 2
         deaths causally related to treatment / all
    0 / 0
    0 / 2
    Pyrexia
         subjects affected / exposed
    2 / 396 (0.51%)
    0 / 404 (0.00%)
         occurrences causally related to treatment / all
    0 / 2
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Catheter site haematoma
         subjects affected / exposed
    1 / 396 (0.25%)
    0 / 404 (0.00%)
         occurrences causally related to treatment / all
    1 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Catheter site haemorrhage
         subjects affected / exposed
    0 / 396 (0.00%)
    1 / 404 (0.25%)
         occurrences causally related to treatment / all
    0 / 0
    1 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Organ failure
         subjects affected / exposed
    0 / 396 (0.00%)
    1 / 404 (0.25%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 1
    Reproductive system and breast disorders
    Pelvic fluid collection
         subjects affected / exposed
    0 / 396 (0.00%)
    1 / 404 (0.25%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Respiratory, thoracic and mediastinal disorders
    Respiratory failure
         subjects affected / exposed
    11 / 396 (2.78%)
    14 / 404 (3.47%)
         occurrences causally related to treatment / all
    1 / 11
    0 / 14
         deaths causally related to treatment / all
    1 / 5
    0 / 5
    Acute respiratory distress syndrome
         subjects affected / exposed
    8 / 396 (2.02%)
    9 / 404 (2.23%)
         occurrences causally related to treatment / all
    1 / 8
    1 / 9
         deaths causally related to treatment / all
    0 / 4
    0 / 3
    Acute respiratory failure
         subjects affected / exposed
    5 / 396 (1.26%)
    3 / 404 (0.74%)
         occurrences causally related to treatment / all
    0 / 5
    0 / 3
         deaths causally related to treatment / all
    0 / 3
    0 / 1
    Pneumothorax
         subjects affected / exposed
    1 / 396 (0.25%)
    4 / 404 (0.99%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 4
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Pulmonary embolism
         subjects affected / exposed
    2 / 396 (0.51%)
    3 / 404 (0.74%)
         occurrences causally related to treatment / all
    1 / 2
    1 / 3
         deaths causally related to treatment / all
    0 / 1
    0 / 0
    Haemoptysis
         subjects affected / exposed
    2 / 396 (0.51%)
    2 / 404 (0.50%)
         occurrences causally related to treatment / all
    2 / 2
    1 / 2
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Hypoxia
         subjects affected / exposed
    2 / 396 (0.51%)
    1 / 404 (0.25%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 1
         deaths causally related to treatment / all
    0 / 1
    0 / 0
    Epistaxis
         subjects affected / exposed
    2 / 396 (0.51%)
    0 / 404 (0.00%)
         occurrences causally related to treatment / all
    2 / 2
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Hypercapnia
         subjects affected / exposed
    1 / 396 (0.25%)
    1 / 404 (0.25%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Pleural effusion
         subjects affected / exposed
    1 / 396 (0.25%)
    1 / 404 (0.25%)
         occurrences causally related to treatment / all
    1 / 1
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Pleurisy
         subjects affected / exposed
    1 / 396 (0.25%)
    1 / 404 (0.25%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Respiratory distress
         subjects affected / exposed
    0 / 396 (0.00%)
    2 / 404 (0.50%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 2
         deaths causally related to treatment / all
    0 / 0
    0 / 2
    Acute pulmonary oedema
         subjects affected / exposed
    0 / 396 (0.00%)
    1 / 404 (0.25%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 1
    Aspiration
         subjects affected / exposed
    0 / 396 (0.00%)
    1 / 404 (0.25%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Atelectasis
         subjects affected / exposed
    1 / 396 (0.25%)
    0 / 404 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Diaphragm muscle weakness
         subjects affected / exposed
    1 / 396 (0.25%)
    0 / 404 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Haemothorax
         subjects affected / exposed
    0 / 396 (0.00%)
    1 / 404 (0.25%)
         occurrences causally related to treatment / all
    0 / 0
    1 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Pneumomediastinum
         subjects affected / exposed
    1 / 396 (0.25%)
    0 / 404 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Pneumonia aspiration
         subjects affected / exposed
    1 / 396 (0.25%)
    0 / 404 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Pulmonary haematoma
         subjects affected / exposed
    1 / 396 (0.25%)
    0 / 404 (0.00%)
         occurrences causally related to treatment / all
    1 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Pulmonary oedema
         subjects affected / exposed
    0 / 396 (0.00%)
    1 / 404 (0.25%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 1
    Respiratory arrest
         subjects affected / exposed
    0 / 396 (0.00%)
    1 / 404 (0.25%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Respiratory tract oedema
         subjects affected / exposed
    1 / 396 (0.25%)
    0 / 404 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Stridor
         subjects affected / exposed
    0 / 396 (0.00%)
    1 / 404 (0.25%)
         occurrences causally related to treatment / all
    0 / 0
    1 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Psychiatric disorders
    Delirium
         subjects affected / exposed
    1 / 396 (0.25%)
    0 / 404 (0.00%)
         occurrences causally related to treatment / all
    1 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Investigations
    Platelet count decreased
         subjects affected / exposed
    2 / 396 (0.51%)
    0 / 404 (0.00%)
         occurrences causally related to treatment / all
    0 / 2
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Coma scale abnormal
         subjects affected / exposed
    1 / 396 (0.25%)
    0 / 404 (0.00%)
         occurrences causally related to treatment / all
    1 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Glutamate dehydrogenase increased
         subjects affected / exposed
    1 / 396 (0.25%)
    0 / 404 (0.00%)
         occurrences causally related to treatment / all
    1 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Haemoglobin decreased
         subjects affected / exposed
    0 / 396 (0.00%)
    1 / 404 (0.25%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Hepatic enzyme abnormal
         subjects affected / exposed
    1 / 396 (0.25%)
    0 / 404 (0.00%)
         occurrences causally related to treatment / all
    1 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    International normalised ratio abnormal
         subjects affected / exposed
    0 / 396 (0.00%)
    1 / 404 (0.25%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Oxygen saturation decreased
         subjects affected / exposed
    1 / 396 (0.25%)
    0 / 404 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Hepatic enzyme increased
         subjects affected / exposed
    1 / 396 (0.25%)
    0 / 404 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Injury, poisoning and procedural complications
    Post procedural haemorrhage
         subjects affected / exposed
    6 / 396 (1.52%)
    2 / 404 (0.50%)
         occurrences causally related to treatment / all
    4 / 6
    1 / 2
         deaths causally related to treatment / all
    1 / 1
    0 / 0
    Overdose
         subjects affected / exposed
    1 / 396 (0.25%)
    4 / 404 (0.99%)
         occurrences causally related to treatment / all
    1 / 1
    3 / 4
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Anastomotic leak
         subjects affected / exposed
    1 / 396 (0.25%)
    2 / 404 (0.50%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 2
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Wound haemorrhage
         subjects affected / exposed
    1 / 396 (0.25%)
    2 / 404 (0.50%)
         occurrences causally related to treatment / all
    1 / 1
    1 / 2
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Subdural haematoma
         subjects affected / exposed
    1 / 396 (0.25%)
    1 / 404 (0.25%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Wound dehiscence
         subjects affected / exposed
    1 / 396 (0.25%)
    1 / 404 (0.25%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Abdominal wound dehiscence
         subjects affected / exposed
    0 / 396 (0.00%)
    1 / 404 (0.25%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Ankle fracture
         subjects affected / exposed
    1 / 396 (0.25%)
    0 / 404 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Chemical peritonitis
         subjects affected / exposed
    0 / 396 (0.00%)
    1 / 404 (0.25%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Endotracheal intubation complication
         subjects affected / exposed
    0 / 396 (0.00%)
    1 / 404 (0.25%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Femur fracture
         subjects affected / exposed
    1 / 396 (0.25%)
    0 / 404 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Gastrointestinal anastomotic leak
         subjects affected / exposed
    0 / 396 (0.00%)
    1 / 404 (0.25%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Intestinal anastomosis complication
         subjects affected / exposed
    1 / 396 (0.25%)
    0 / 404 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Post procedural haematoma
         subjects affected / exposed
    1 / 396 (0.25%)
    0 / 404 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Procedural haemorrhage
         subjects affected / exposed
    1 / 396 (0.25%)
    0 / 404 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Cardiac disorders
    Cardiac arrest
         subjects affected / exposed
    10 / 396 (2.53%)
    11 / 404 (2.72%)
         occurrences causally related to treatment / all
    1 / 10
    0 / 11
         deaths causally related to treatment / all
    0 / 3
    0 / 5
    Atrial fibrillation
         subjects affected / exposed
    6 / 396 (1.52%)
    5 / 404 (1.24%)
         occurrences causally related to treatment / all
    1 / 6
    2 / 5
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Bradycardia
         subjects affected / exposed
    4 / 396 (1.01%)
    2 / 404 (0.50%)
         occurrences causally related to treatment / all
    0 / 4
    0 / 2
         deaths causally related to treatment / all
    0 / 1
    0 / 1
    Cardiac failure acute
         subjects affected / exposed
    4 / 396 (1.01%)
    2 / 404 (0.50%)
         occurrences causally related to treatment / all
    0 / 4
    0 / 2
         deaths causally related to treatment / all
    0 / 4
    0 / 2
    Cardiopulmonary failure
         subjects affected / exposed
    2 / 396 (0.51%)
    3 / 404 (0.74%)
         occurrences causally related to treatment / all
    0 / 2
    0 / 3
         deaths causally related to treatment / all
    0 / 2
    0 / 3
    Myocardial infarction
         subjects affected / exposed
    1 / 396 (0.25%)
    3 / 404 (0.74%)
         occurrences causally related to treatment / all
    0 / 1
    2 / 3
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Cardio-respiratory arrest
         subjects affected / exposed
    3 / 396 (0.76%)
    0 / 404 (0.00%)
         occurrences causally related to treatment / all
    1 / 3
    0 / 0
         deaths causally related to treatment / all
    1 / 3
    0 / 0
    Ventricular tachycardia
         subjects affected / exposed
    1 / 396 (0.25%)
    2 / 404 (0.50%)
         occurrences causally related to treatment / all
    0 / 1
    1 / 2
         deaths causally related to treatment / all
    0 / 0
    0 / 1
    Arrhythmia
         subjects affected / exposed
    2 / 396 (0.51%)
    0 / 404 (0.00%)
         occurrences causally related to treatment / all
    0 / 2
    0 / 0
         deaths causally related to treatment / all
    0 / 1
    0 / 0
    Cardiac failure
         subjects affected / exposed
    1 / 396 (0.25%)
    1 / 404 (0.25%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 1
         deaths causally related to treatment / all
    0 / 1
    0 / 1
    Cardiogenic shock
         subjects affected / exposed
    1 / 396 (0.25%)
    1 / 404 (0.25%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 1
         deaths causally related to treatment / all
    0 / 1
    0 / 1
    Supraventricular tachycardia
         subjects affected / exposed
    1 / 396 (0.25%)
    1 / 404 (0.25%)
         occurrences causally related to treatment / all
    1 / 1
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Acute coronary syndrome
         subjects affected / exposed
    0 / 396 (0.00%)
    1 / 404 (0.25%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 1
    Acute myocardial infarction
         subjects affected / exposed
    1 / 396 (0.25%)
    0 / 404 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Aortic valve incompetence
         subjects affected / exposed
    0 / 396 (0.00%)
    1 / 404 (0.25%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Atrial flutter
         subjects affected / exposed
    1 / 396 (0.25%)
    0 / 404 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Atrial tachycardia
         subjects affected / exposed
    1 / 396 (0.25%)
    0 / 404 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Cardiac failure congestive
         subjects affected / exposed
    0 / 396 (0.00%)
    1 / 404 (0.25%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Congestive cardiomyopathy
         subjects affected / exposed
    1 / 396 (0.25%)
    0 / 404 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 1
    0 / 0
    Coronary artery stenosis
         subjects affected / exposed
    0 / 396 (0.00%)
    1 / 404 (0.25%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Intracardiac thrombus
         subjects affected / exposed
    1 / 396 (0.25%)
    0 / 404 (0.00%)
         occurrences causally related to treatment / all
    1 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Myocarditis
         subjects affected / exposed
    0 / 396 (0.00%)
    1 / 404 (0.25%)
         occurrences causally related to treatment / all
    0 / 0
    1 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Pericarditis
         subjects affected / exposed
    0 / 396 (0.00%)
    1 / 404 (0.25%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Pulseless electrical activity
         subjects affected / exposed
    0 / 396 (0.00%)
    1 / 404 (0.25%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Nervous system disorders
    Ischaemic stroke
         subjects affected / exposed
    4 / 396 (1.01%)
    0 / 404 (0.00%)
         occurrences causally related to treatment / all
    0 / 4
    0 / 0
         deaths causally related to treatment / all
    0 / 1
    0 / 0
    Cerebral infarction
         subjects affected / exposed
    1 / 396 (0.25%)
    2 / 404 (0.50%)
         occurrences causally related to treatment / all
    1 / 1
    0 / 2
         deaths causally related to treatment / all
    1 / 1
    0 / 0
    Embolic cerebral infarction
         subjects affected / exposed
    2 / 396 (0.51%)
    1 / 404 (0.25%)
         occurrences causally related to treatment / all
    1 / 2
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Cerebral haemorrhage
         subjects affected / exposed
    1 / 396 (0.25%)
    1 / 404 (0.25%)
         occurrences causally related to treatment / all
    1 / 1
    1 / 1
         deaths causally related to treatment / all
    1 / 1
    0 / 0
    Cerebrovascular accident
         subjects affected / exposed
    1 / 396 (0.25%)
    1 / 404 (0.25%)
         occurrences causally related to treatment / all
    1 / 1
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 1
    Epilepsy
         subjects affected / exposed
    1 / 396 (0.25%)
    1 / 404 (0.25%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Intensive care unit acquired weakness
         subjects affected / exposed
    0 / 396 (0.00%)
    2 / 404 (0.50%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 2
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Brain hypoxia
         subjects affected / exposed
    0 / 396 (0.00%)
    1 / 404 (0.25%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 1
    Brain injury
         subjects affected / exposed
    1 / 396 (0.25%)
    0 / 404 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 1
    0 / 0
    Brain oedema
         subjects affected / exposed
    0 / 396 (0.00%)
    1 / 404 (0.25%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Brain stem ischaemia
         subjects affected / exposed
    0 / 396 (0.00%)
    1 / 404 (0.25%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 1
    Cerebral atrophy
         subjects affected / exposed
    1 / 396 (0.25%)
    0 / 404 (0.00%)
         occurrences causally related to treatment / all
    1 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Cerebral haematoma
         subjects affected / exposed
    1 / 396 (0.25%)
    0 / 404 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Facial paralysis
         subjects affected / exposed
    0 / 396 (0.00%)
    1 / 404 (0.25%)
         occurrences causally related to treatment / all
    0 / 0
    1 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Haemorrhage intracranial
         subjects affected / exposed
    1 / 396 (0.25%)
    0 / 404 (0.00%)
         occurrences causally related to treatment / all
    1 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Hypercapnic coma
         subjects affected / exposed
    1 / 396 (0.25%)
    0 / 404 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 1
    0 / 0
    Hypoxic-ischaemic encephalopathy
         subjects affected / exposed
    0 / 396 (0.00%)
    1 / 404 (0.25%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Paraplegia
         subjects affected / exposed
    0 / 396 (0.00%)
    1 / 404 (0.25%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Polyneuropathy
         subjects affected / exposed
    1 / 396 (0.25%)
    0 / 404 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Posterior reversible encephalopathy syndrome
         subjects affected / exposed
    1 / 396 (0.25%)
    0 / 404 (0.00%)
         occurrences causally related to treatment / all
    1 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Seizure
         subjects affected / exposed
    1 / 396 (0.25%)
    0 / 404 (0.00%)
         occurrences causally related to treatment / all
    1 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Syncope
         subjects affected / exposed
    1 / 396 (0.25%)
    0 / 404 (0.00%)
         occurrences causally related to treatment / all
    1 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Blood and lymphatic system disorders
    Thrombocytopenia
         subjects affected / exposed
    10 / 396 (2.53%)
    12 / 404 (2.97%)
         occurrences causally related to treatment / all
    2 / 10
    2 / 12
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Anaemia
         subjects affected / exposed
    5 / 396 (1.26%)
    7 / 404 (1.73%)
         occurrences causally related to treatment / all
    1 / 5
    1 / 7
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Disseminated intravascular coagulation
         subjects affected / exposed
    1 / 396 (0.25%)
    2 / 404 (0.50%)
         occurrences causally related to treatment / all
    0 / 1
    1 / 2
         deaths causally related to treatment / all
    0 / 1
    0 / 1
    Coagulopathy
         subjects affected / exposed
    0 / 396 (0.00%)
    1 / 404 (0.25%)
         occurrences causally related to treatment / all
    0 / 0
    1 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Eosinophilia
         subjects affected / exposed
    1 / 396 (0.25%)
    0 / 404 (0.00%)
         occurrences causally related to treatment / all
    1 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Haemolysis
         subjects affected / exposed
    0 / 396 (0.00%)
    1 / 404 (0.25%)
         occurrences causally related to treatment / all
    0 / 0
    1 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Leukocytosis
         subjects affected / exposed
    0 / 396 (0.00%)
    1 / 404 (0.25%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Pancytopenia
         subjects affected / exposed
    0 / 396 (0.00%)
    1 / 404 (0.25%)
         occurrences causally related to treatment / all
    0 / 0
    1 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Ear and labyrinth disorders
    Deafness bilateral
         subjects affected / exposed
    0 / 396 (0.00%)
    1 / 404 (0.25%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Gastrointestinal disorders
    Intestinal ischaemia
         subjects affected / exposed
    7 / 396 (1.77%)
    6 / 404 (1.49%)
         occurrences causally related to treatment / all
    2 / 7
    1 / 6
         deaths causally related to treatment / all
    0 / 2
    0 / 3
    Gastrointestinal haemorrhage
         subjects affected / exposed
    2 / 396 (0.51%)
    5 / 404 (1.24%)
         occurrences causally related to treatment / all
    1 / 2
    2 / 5
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Gastrointestinal necrosis
         subjects affected / exposed
    3 / 396 (0.76%)
    2 / 404 (0.50%)
         occurrences causally related to treatment / all
    0 / 3
    0 / 2
         deaths causally related to treatment / all
    0 / 2
    0 / 2
    Intestinal perforation
         subjects affected / exposed
    3 / 396 (0.76%)
    1 / 404 (0.25%)
         occurrences causally related to treatment / all
    0 / 3
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Large intestine perforation
         subjects affected / exposed
    1 / 396 (0.25%)
    2 / 404 (0.50%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 2
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Abdominal pain
         subjects affected / exposed
    2 / 396 (0.51%)
    0 / 404 (0.00%)
         occurrences causally related to treatment / all
    0 / 2
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Abdominal hernia
         subjects affected / exposed
    0 / 396 (0.00%)
    1 / 404 (0.25%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Constipation
         subjects affected / exposed
    1 / 396 (0.25%)
    0 / 404 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Diarrhoea
         subjects affected / exposed
    1 / 396 (0.25%)
    0 / 404 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 32
    0 / 36
    Fistula of small intestine
         subjects affected / exposed
    0 / 396 (0.00%)
    1 / 404 (0.25%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Gastrointestinal disorder
         subjects affected / exposed
    0 / 396 (0.00%)
    1 / 404 (0.25%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Gastrointestinal perforation
         subjects affected / exposed
    1 / 396 (0.25%)
    0 / 404 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Gastrointestinal ulcer haemorrhage
         subjects affected / exposed
    1 / 396 (0.25%)
    0 / 404 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Gastrointestinal wall abnormal
         subjects affected / exposed
    0 / 396 (0.00%)
    1 / 404 (0.25%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Hernial eventration
         subjects affected / exposed
    1 / 396 (0.25%)
    0 / 404 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Intestinal haemorrhage
         subjects affected / exposed
    1 / 396 (0.25%)
    0 / 404 (0.00%)
         occurrences causally related to treatment / all
    1 / 1
    0 / 0
         deaths causally related to treatment / all
    1 / 1
    0 / 0
    Intra-abdominal haematoma
         subjects affected / exposed
    1 / 396 (0.25%)
    0 / 404 (0.00%)
         occurrences causally related to treatment / all
    1 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Intra-abdominal haemorrhage
         subjects affected / exposed
    1 / 396 (0.25%)
    0 / 404 (0.00%)
         occurrences causally related to treatment / all
    1 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Mesenteric artery thrombosis
         subjects affected / exposed
    0 / 396 (0.00%)
    1 / 404 (0.25%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 1
    Mesenteric haemorrhage
         subjects affected / exposed
    1 / 396 (0.25%)
    0 / 404 (0.00%)
         occurrences causally related to treatment / all
    1 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Mesenteric vein thrombosis
         subjects affected / exposed
    0 / 396 (0.00%)
    1 / 404 (0.25%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Mouth haemorrhage
         subjects affected / exposed
    1 / 396 (0.25%)
    0 / 404 (0.00%)
         occurrences causally related to treatment / all
    1 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Oesophageal haemorrhage
         subjects affected / exposed
    1 / 396 (0.25%)
    0 / 404 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Pancreatic haemorrhage
         subjects affected / exposed
    1 / 396 (0.25%)
    0 / 404 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Rectal haemorrhage
         subjects affected / exposed
    0 / 396 (0.00%)
    1 / 404 (0.25%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Retroperitoneal haematoma
         subjects affected / exposed
    1 / 396 (0.25%)
    0 / 404 (0.00%)
         occurrences causally related to treatment / all
    1 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Retroperitoneal haemorrhage
         subjects affected / exposed
    1 / 396 (0.25%)
    0 / 404 (0.00%)
         occurrences causally related to treatment / all
    1 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Thrombosis mesenteric vessel
         subjects affected / exposed
    1 / 396 (0.25%)
    0 / 404 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 1
    0 / 0
    Upper gastrointestinal haemorrhage
         subjects affected / exposed
    0 / 396 (0.00%)
    1 / 404 (0.25%)
         occurrences causally related to treatment / all
    0 / 0
    1 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Hepatobiliary disorders
    Hepatic function abnormal
         subjects affected / exposed
    3 / 396 (0.76%)
    2 / 404 (0.50%)
         occurrences causally related to treatment / all
    0 / 3
    0 / 2
         deaths causally related to treatment / all
    0 / 1
    0 / 0
    Ischaemic hepatitis
         subjects affected / exposed
    1 / 396 (0.25%)
    3 / 404 (0.74%)
         occurrences causally related to treatment / all
    0 / 1
    2 / 3
         deaths causally related to treatment / all
    0 / 1
    0 / 0
    Hepatocellular injury
         subjects affected / exposed
    2 / 396 (0.51%)
    1 / 404 (0.25%)
         occurrences causally related to treatment / all
    1 / 2
    1 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Acute hepatic failure
         subjects affected / exposed
    1 / 396 (0.25%)
    1 / 404 (0.25%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Cholecystitis acute
         subjects affected / exposed
    0 / 396 (0.00%)
    1 / 404 (0.25%)
         occurrences causally related to treatment / all
    0 / 0
    1 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Hepatic failure
         subjects affected / exposed
    1 / 396 (0.25%)
    0 / 404 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Hepatic necrosis
         subjects affected / exposed
    1 / 396 (0.25%)
    0 / 404 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Renal and urinary disorders
    Acute kidney injury
         subjects affected / exposed
    14 / 396 (3.54%)
    10 / 404 (2.48%)
         occurrences causally related to treatment / all
    2 / 14
    3 / 10
         deaths causally related to treatment / all
    0 / 1
    0 / 0
    Renal failure
         subjects affected / exposed
    3 / 396 (0.76%)
    1 / 404 (0.25%)
         occurrences causally related to treatment / all
    1 / 3
    0 / 1
         deaths causally related to treatment / all
    0 / 1
    0 / 0
    Renal impairment
         subjects affected / exposed
    2 / 396 (0.51%)
    1 / 404 (0.25%)
         occurrences causally related to treatment / all
    0 / 2
    1 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Anuria
         subjects affected / exposed
    1 / 396 (0.25%)
    1 / 404 (0.25%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Haematuria
         subjects affected / exposed
    1 / 396 (0.25%)
    0 / 404 (0.00%)
         occurrences causally related to treatment / all
    1 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Renal ischaemia
         subjects affected / exposed
    1 / 396 (0.25%)
    0 / 404 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Renal tubular necrosis
         subjects affected / exposed
    0 / 396 (0.00%)
    1 / 404 (0.25%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Urinary bladder haemorrhage
         subjects affected / exposed
    0 / 396 (0.00%)
    1 / 404 (0.25%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Endocrine disorders
    Adrenal haemorrhage
         subjects affected / exposed
    1 / 396 (0.25%)
    0 / 404 (0.00%)
         occurrences causally related to treatment / all
    1 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Musculoskeletal and connective tissue disorders
    Muscle haemorrhage
         subjects affected / exposed
    2 / 396 (0.51%)
    0 / 404 (0.00%)
         occurrences causally related to treatment / all
    2 / 2
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Compartment syndrome
         subjects affected / exposed
    0 / 396 (0.00%)
    1 / 404 (0.25%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Rhabdomyolysis
         subjects affected / exposed
    0 / 396 (0.00%)
    1 / 404 (0.25%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Infections and infestations
    Septic shock
         subjects affected / exposed
    28 / 396 (7.07%)
    30 / 404 (7.43%)
         occurrences causally related to treatment / all
    1 / 28
    1 / 30
         deaths causally related to treatment / all
    1 / 25
    1 / 28
    Sepsis
         subjects affected / exposed
    8 / 396 (2.02%)
    11 / 404 (2.72%)
         occurrences causally related to treatment / all
    0 / 8
    0 / 11
         deaths causally related to treatment / all
    0 / 7
    0 / 10
    Pneumonia
         subjects affected / exposed
    8 / 396 (2.02%)
    10 / 404 (2.48%)
         occurrences causally related to treatment / all
    0 / 8
    0 / 10
         deaths causally related to treatment / all
    0 / 1
    0 / 3
    Peritonitis
         subjects affected / exposed
    3 / 396 (0.76%)
    3 / 404 (0.74%)
         occurrences causally related to treatment / all
    0 / 3
    0 / 3
         deaths causally related to treatment / all
    0 / 0
    0 / 1
    Gangrene
         subjects affected / exposed
    3 / 396 (0.76%)
    2 / 404 (0.50%)
         occurrences causally related to treatment / all
    0 / 3
    0 / 2
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Necrotising fasciitis
         subjects affected / exposed
    1 / 396 (0.25%)
    3 / 404 (0.74%)
         occurrences causally related to treatment / all
    0 / 1
    1 / 3
         deaths causally related to treatment / all
    0 / 0
    1 / 1
    Endocarditis
         subjects affected / exposed
    2 / 396 (0.51%)
    1 / 404 (0.25%)
         occurrences causally related to treatment / all
    0 / 2
    0 / 2
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Endocarditis bacterial
         subjects affected / exposed
    1 / 396 (0.25%)
    1 / 404 (0.25%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 1
         deaths causally related to treatment / all
    0 / 1
    0 / 0
    Abdominal sepsis
         subjects affected / exposed
    0 / 396 (0.00%)
    1 / 404 (0.25%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Abdominal wall abscess
         subjects affected / exposed
    1 / 396 (0.25%)
    0 / 404 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Abscess limb
         subjects affected / exposed
    1 / 396 (0.25%)
    0 / 404 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Bacteraemia
         subjects affected / exposed
    0 / 396 (0.00%)
    1 / 404 (0.25%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Catheter site infection
         subjects affected / exposed
    1 / 396 (0.25%)
    0 / 404 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Cellulitis
         subjects affected / exposed
    0 / 396 (0.00%)
    1 / 404 (0.25%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Cellulitis gangrenous
         subjects affected / exposed
    0 / 396 (0.00%)
    1 / 404 (0.25%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Fungal sepsis
         subjects affected / exposed
    1 / 396 (0.25%)
    0 / 404 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Haematoma infection
         subjects affected / exposed
    1 / 396 (0.25%)
    0 / 404 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Hepatic infection
         subjects affected / exposed
    1 / 396 (0.25%)
    0 / 404 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Herpes simplex pneumonia
         subjects affected / exposed
    0 / 396 (0.00%)
    1 / 404 (0.25%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Infection
         subjects affected / exposed
    0 / 396 (0.00%)
    1 / 404 (0.25%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Infectious pleural effusion
         subjects affected / exposed
    0 / 396 (0.00%)
    1 / 404 (0.25%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Infective aneurysm
         subjects affected / exposed
    1 / 396 (0.25%)
    0 / 404 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Influenza
         subjects affected / exposed
    0 / 396 (0.00%)
    1 / 404 (0.25%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Liver abscess
         subjects affected / exposed
    1 / 396 (0.25%)
    0 / 404 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Lung infection
         subjects affected / exposed
    1 / 396 (0.25%)
    0 / 404 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Pneumococcal sepsis
         subjects affected / exposed
    1 / 396 (0.25%)
    0 / 404 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 1
    0 / 0
    Pneumonia staphylococcal
         subjects affected / exposed
    0 / 396 (0.00%)
    1 / 404 (0.25%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 1
    Pneumonia fungal
         subjects affected / exposed
    1 / 396 (0.25%)
    0 / 404 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Postoperative wound infection
         subjects affected / exposed
    0 / 396 (0.00%)
    1 / 404 (0.25%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Renal abscess
         subjects affected / exposed
    1 / 396 (0.25%)
    0 / 404 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Septic embolus
         subjects affected / exposed
    0 / 396 (0.00%)
    1 / 404 (0.25%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Staphylococcal infection
         subjects affected / exposed
    0 / 396 (0.00%)
    1 / 404 (0.25%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Staphylococcal sepsis
         subjects affected / exposed
    1 / 396 (0.25%)
    0 / 404 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Systemic candida
         subjects affected / exposed
    0 / 396 (0.00%)
    1 / 404 (0.25%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Tracheobronchitis
         subjects affected / exposed
    1 / 396 (0.25%)
    0 / 404 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Varicella zoster pneumonia
         subjects affected / exposed
    1 / 396 (0.25%)
    0 / 404 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Metabolism and nutrition disorders
    Diabetic ketoacidosis
         subjects affected / exposed
    1 / 396 (0.25%)
    0 / 404 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Electrolyte imbalance
         subjects affected / exposed
    1 / 396 (0.25%)
    0 / 404 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Hyperkalaemia
         subjects affected / exposed
    1 / 396 (0.25%)
    0 / 404 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Hypernatraemia
         subjects affected / exposed
    0 / 396 (0.00%)
    1 / 404 (0.25%)
         occurrences causally related to treatment / all
    0 / 0
    1 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Hypocalcaemia
         subjects affected / exposed
    0 / 396 (0.00%)
    1 / 404 (0.25%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Hypoglycaemia
         subjects affected / exposed
    1 / 396 (0.25%)
    0 / 404 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Hypovolaemia
         subjects affected / exposed
    0 / 396 (0.00%)
    1 / 404 (0.25%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Malnutrition
         subjects affected / exposed
    0 / 396 (0.00%)
    1 / 404 (0.25%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Frequency threshold for reporting non-serious adverse events: 5%
    Non-serious adverse events
    ART-123 Placebo
    Total subjects affected by non serious adverse events
         subjects affected / exposed
    271 / 396 (68.43%)
    264 / 404 (65.35%)
    Vascular disorders
    Hypotension
         subjects affected / exposed
    23 / 396 (5.81%)
    24 / 404 (5.94%)
         occurrences all number
    30
    27
    Hypertension
         subjects affected / exposed
    23 / 396 (5.81%)
    25 / 404 (6.19%)
         occurrences all number
    25
    28
    Cardiac disorders
    Atrial fibrillation
         subjects affected / exposed
    51 / 396 (12.88%)
    52 / 404 (12.87%)
         occurrences all number
    56
    60
    Blood and lymphatic system disorders
    Anaemia
         subjects affected / exposed
    99 / 396 (25.00%)
    78 / 404 (19.31%)
         occurrences all number
    150
    100
    Thrombocytopenia
         subjects affected / exposed
    40 / 396 (10.10%)
    51 / 404 (12.62%)
         occurrences all number
    52
    62
    General disorders and administration site conditions
    Pyrexia
         subjects affected / exposed
    39 / 396 (9.85%)
    33 / 404 (8.17%)
         occurrences all number
    50
    38
    Oedema peripheral
         subjects affected / exposed
    20 / 396 (5.05%)
    17 / 404 (4.21%)
         occurrences all number
    21
    17
    Gastrointestinal disorders
    Constipation
         subjects affected / exposed
    37 / 396 (9.34%)
    37 / 404 (9.16%)
         occurrences all number
    37
    40
    Diarrhoea
         subjects affected / exposed
    31 / 396 (7.83%)
    36 / 404 (8.91%)
         occurrences all number
    32
    36
    Nausea
         subjects affected / exposed
    31 / 396 (7.83%)
    18 / 404 (4.46%)
         occurrences all number
    34
    19
    Respiratory, thoracic and mediastinal disorders
    Pleural effusion
         subjects affected / exposed
    27 / 396 (6.82%)
    31 / 404 (7.67%)
         occurrences all number
    30
    34
    Renal and urinary disorders
    Acute kidney injury
         subjects affected / exposed
    28 / 396 (7.07%)
    13 / 404 (3.22%)
         occurrences all number
    31
    13
    Psychiatric disorders
    Delirium
         subjects affected / exposed
    31 / 396 (7.83%)
    21 / 404 (5.20%)
         occurrences all number
    31
    21
    Insomnia
         subjects affected / exposed
    20 / 396 (5.05%)
    21 / 404 (5.20%)
         occurrences all number
    20
    21
    Infections and infestations
    Pneumonia
         subjects affected / exposed
    21 / 396 (5.30%)
    22 / 404 (5.45%)
         occurrences all number
    22
    22
    Metabolism and nutrition disorders
    Hypokalaemia
         subjects affected / exposed
    83 / 396 (20.96%)
    69 / 404 (17.08%)
         occurrences all number
    100
    83
    Hypophosphataemia
         subjects affected / exposed
    46 / 396 (11.62%)
    39 / 404 (9.65%)
         occurrences all number
    50
    40
    Hyperglycaemia
         subjects affected / exposed
    37 / 396 (9.34%)
    34 / 404 (8.42%)
         occurrences all number
    40
    36
    Hypoglycaemia
         subjects affected / exposed
    25 / 396 (6.31%)
    31 / 404 (7.67%)
         occurrences all number
    28
    33
    Hyperkalaemia
         subjects affected / exposed
    83 / 396 (20.96%)
    69 / 404 (17.08%)
         occurrences all number
    30
    21
    Hypernatraemia
         subjects affected / exposed
    21 / 396 (5.30%)
    23 / 404 (5.69%)
         occurrences all number
    25
    22
    Hypomagnesaemia
         subjects affected / exposed
    25 / 396 (6.31%)
    19 / 404 (4.70%)
         occurrences all number
    26
    23
    Fluid overload
         subjects affected / exposed
    21 / 396 (5.30%)
    16 / 404 (3.96%)
         occurrences all number
    21
    16
    Hypocalcaemia
         subjects affected / exposed
    21 / 396 (5.30%)
    11 / 404 (2.72%)
         occurrences all number
    22
    12

    More information

    Close Top of page

    Substantial protocol amendments (globally)

    Were there any global substantial amendments to the protocol? Yes
    Date
    Amendment
    19 Sep 2013
    Amendment v2.0 (13Aug2013) was considered substantial due to changes in the inclusion criteria for 1)alternate criteria for platelet count count added for a 30% decrease in platelets in 24 hours to include subjects with early onset thrombocytopenia, 2) time window for developing evidence of infection revised from 24 to 36 hours to allow the development of infection and time to randomization from 12 to 15 hours due to sites not having enough time to gain legally authorized consent and randomize.
    05 Sep 2014
    Amendment v3.0 (21July2014) was considered substantial since it revised an exclusion criteria that had previously excluded subjects on renal replacement treatment. AKPA provided results of a phase 1 study indicating end-stage renal disease (ESRD) subjects undergoing hemodialysis supporting the enrollment of RRT subjects in study 3-001 without any dose adjustment to the study drug.
    27 Nov 2015
    Amendment v4.0 (23Oct2015) was considered substantial due to changes widening the inclusion criteria timing. The purpose of this change was to provide more time for investigators to enroll subjects before the time window expires. Therefore in Version 4 of the protocol a change was made to allow up to 36 hours after the first qualifying INR to allow the sites to identify and enroll subjects in a timely manner before the time window expires. This will only occur in cases where the first qualifying INR precedes both thrombocytopenia and organ dysfunction. In consultation with clinical experts, the Sponsor has concluded that the change is justified as it is unlikely to result in a meaningful clinical difference in disease progression that would impact outcomes. The Scenario 2 was eliminated because it was difficult for the sites to justify obtaining the informed consent for the sole purpose of obtaining an INR. The deletion of Scenario 2 does not impact the inclusion criteria for the study.

    Interruptions (globally)

    Were there any global interruptions to the trial? No

    Limitations and caveats

    Limitations of the trial such as small numbers of subjects analysed or technical problems leading to unreliable data.
    None reported
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sun May 04 22:50:25 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA